Drug Profile
Influenza-A-virus-H1N1-vaccine - Codagenix
Alternative Names: CODA-VAX H1N1; CodaVax; CodaVax™-H1N1; H1N1 live-attenuated influenza vaccine - CodagenixLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Codagenix
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in Australia (Intranasal, Spray)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Intranasal, Spray)
- 14 Jun 2022 Codagenix completes dosing in a phase I trial in Influenza virus infections (Prevention) in Australia (IM, Injection) (NCT05223179)